We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

By LabMedica International staff writers
Posted on 04 Jun 2025

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. More...

With more than 3.3 million men in the United States diagnosed with prostate cancer and one in 44 dying from the disease, early and accurate survival prediction is vital. However, accurately predicting the overall survival of patients with PAC has long been a clinical challenge due to the disease's complex and varied nature. While early diagnosis improves treatment outcomes, the diverse progression patterns of this cancer make precise prognosis difficult. Now, scientists have developed a machine learning-based method that uses ensemble models to deliver near-perfect survival estimates for patients with PAC.

In a study led by University of Sharjah (Sharjah, UAE) and Near East University (Istanbul, Turkey), the researchers applied and evaluated eight machine learning ensemble methods to predict overall survival outcomes in prostate adenocarcinoma patients, using clinical and genomic data from The Cancer Genome Atlas (TCGA) PanCancer Atlas. The models assessed in the study include Random Forest (RF), AdaBoost, Gradient Boosting (GB), Extreme Gradient Boosting (XGB), LightGBM (LGBM), CatBoost, Hard Voting Classifier (HVC), and Support Vector Classifier (SVC). These ensemble techniques combine the predictive power of multiple algorithms to improve model performance. By using essential performance indicators such as accuracy, precision, recall, F1 score, and ROC AUC score, the researchers determined how well each method predicted patient survival.

The findings, published in the journal Computers in Biology and Medicine, reveal that among the eight models tested, GB emerged as the top performer, achieving a perfect score of 1.0 in accuracy, precision, recall, and F1 score, and 0.99 for ROC AUC. Other high-performing models included RF and AdaBoost, which also demonstrated strong predictive capability and robustness in distinguishing between positive and negative survival outcomes. The ability of these models to accurately identify high-risk and low-risk patients could offer critical support for clinical decision-making and individualized patient care. The use of these AI-driven models could greatly enhance the clinical understanding of PAC and overcome existing barriers by offering tailored prognostic insights, potentially leading to improved outcomes and optimized treatment strategies.

“The outstanding performances of GB are suggestive that it is an ensemble model, highly capable of predicting PAC (Prostate adenocarcinoma), because it identifies all true positive cases, and can minimize the negative cases as well as can be clinically integrated,” the study authors wrote. “RF performances showed its ability to distinguish between positive and negative cases of PAC highlighting its high level of accuracy, especially in predicting the presence of PAC.”


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Serological Pipet Controller
PIPETBOY GENIUS
New
Pipette
Accumax Smart Series
New
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The VeraBIND Tau assay is a novel blood test that identifies the presence of active tau pathology (Photo courtesy of 123RF)

First Blood-Based Test Measures Key Alzheimer's Biomarker in Asymptomatic and Symptomatic Individuals

Alzheimer’s disease (AD), the sixth leading cause of death in the United States, affects an estimated 7.2 million Americans aged 65 or older. Current diagnostic methods for AD are often invasive, expensive,... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.